Napoletano Chiara, Steentoff Catharina, Battisti Federico, Ye Zilu, Rahimi Hassan, Zizzari Ilaria Grazia, Dionisi Marco, Cerbelli Bruna, Tomao Federica, French Deborah, d'Amati Giulia, Panici Pierluigi Benedetti, Vakhrushev Sergey, Clausen Henrik, Nuti Marianna, Rughetti Aurelia
Department of Experimental Medicine, "Sapienza" University of Rome, Viale Regina Elena, 00185 Rome, Italy.
Copenhagen Center for Glycomics, Department of Cellular and Molecular Medicine and School of Dentistry, Faculty of Health Sciences, University of Copenhagen, Blegdamsvej 3, DK-2200 Copenhagen N, Denmark.
Cancers (Basel). 2020 Oct 1;12(10):2841. doi: 10.3390/cancers12102841.
Glycosylation, the posttranslational linking of sugar molecules to proteins, is notoriously altered during tumor transformation. More specifically in carcinomas, GalNAc-type -glycosylation, is characterized by biosynthetically immature truncated glycans present on the cancer cell surface, which profoundly impact anti-tumor immune recognition. The tumor-associated glycan pattern may thus be regarded as a biomarker of immune modulation. In epithelial ovarian cancer (EOC) there is a particular lack of specific biomarkers and molecular targets to aid early diagnosis and develop novel therapeutic interventions. The aim of this study was to investigate the ovarian cancer -glycoproteome and identify tumor-associated glycoproteins relevant in tumor-dendritic cell (DC) interactions, mediated by macrophage galactose-like C type lectin (MGL), which recognizes the tumor-associated Tn -glycan. Lectin weak affinity chromatography (LWAC) was employed to probe the -glycopeptidome by MGL and agglutinin (VVA) lectin using glycoengineered ovarian cancer cell lines and ovarian cancer tissues as input material. Biochemical and bioinformatics analysis gave information on the glycan arrangement recognized by MGL in tumor cells. The potential MGL binders identified were located, as expected, at the cell membrane, but also within the intracellular compartment and the matrisome, suggesting that MGL in vivo may play a complex role in sensing microenvironmental cues. The tumor glycoproteins binders for MGL may become relevant to characterize the interaction between the immune system and tumor progression and contribute to the design of glycan targeting-based strategies for EOC immunotherapeutic interventions.
糖基化是糖分子与蛋白质的翻译后连接过程,在肿瘤转化过程中会发生显著改变。更具体地说,在 carcinomas 中,GalNAc 型 - 糖基化的特征是癌细胞表面存在生物合成不成熟的截短聚糖,这对抗肿瘤免疫识别有深远影响。因此,肿瘤相关聚糖模式可被视为免疫调节的生物标志物。在上皮性卵巢癌(EOC)中,尤其缺乏有助于早期诊断和开发新型治疗干预措施的特异性生物标志物和分子靶点。本研究的目的是研究卵巢癌 - 糖蛋白质组,并鉴定在肿瘤 - 树突状细胞(DC)相互作用中相关的肿瘤相关糖蛋白,这种相互作用由巨噬细胞半乳糖样 C 型凝集素(MGL)介导,MGL 可识别肿瘤相关的 Tn - 聚糖。采用凝集素弱亲和色谱法(LWAC),以糖工程化卵巢癌细胞系和卵巢癌组织为输入材料,用 MGL 和凝集素(VVA)凝集素探测 - 糖肽组。生化和生物信息学分析提供了关于肿瘤细胞中 MGL 识别的聚糖排列的信息。如预期的那样,鉴定出的潜在 MGL 结合物位于细胞膜,但也存在于细胞内区室和基质体中,这表明 MGL 在体内可能在感知微环境线索方面发挥复杂作用。MGL 的肿瘤糖蛋白结合物可能与表征免疫系统与肿瘤进展之间的相互作用相关,并有助于设计基于聚糖靶向的 EOC 免疫治疗干预策略。